Arcus backs TIGIT combo by offering glimpse at positive data from axed trial
Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
